Joel E Vargas-Ahumada

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Positron Emission Tomography

Convolutional Neural Network

Prostate Cancer

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Diana Trujillo-Benítez, Myrna Luna-Gutiérrez, José G Aguirre-De Paz, Pedro Cruz-Nova, Gerardo Bravo-Villegas, Joel E Vargas-Ahumada, Paola Vallejo-Armenta, Enrique Morales-Ávila, Nallely Jiménez-Mancilla, Rigoberto Oros-Pantoja, Clara Leticia Santos Cuevas, Erika Azorín-Vega, Blanca Ocampo-Garcia, Guillermina Ferro-Flores
68 Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases. Pharmaceutics 16 (4) (2024)
Diana Trujillo-Benítez, Myrna Luna-Gutiérrez, José G Aguirre-De Paz, Pedro Cruz-Nova, Gerardo Bravo-Villegas, Joel E Vargas-Ahumada, Paola Vallejo-Armenta, Enrique Morales-Ávila, Nallely Jiménez-Mancilla, Rigoberto Oros-Pantoja, Clara Leticia Santos Cuevas, Erika Azorín-Vega, Blanca Ocampo-Garcia, Guillermina Ferro-Flores
68 Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases. Pharmaceutics 16 (4) (2024)
Joel E Vargas-Ahumada, Sofía Denisse González-Rueda, Fabio Andrés Sinisterra-Solís, Pamela Casanova-Triviño, Quetzali Pitalúa-Cortés, Irma Soldevilla-Gallardo, Anna Scavuzzo, Miguel Angel Jimenez-Ríos, Francisco Osvaldo García-Pérez
Diagnostic Performance of 99m Tc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18 F-PSMA-1007 PET/CT. Cancers 15 (24) (2023)
Joel E Vargas-Ahumada, Sofía Denisse González-Rueda, Fabio Andrés Sinisterra-Solís, Pamela Casanova-Triviño, Quetzali Pitalúa-Cortés, Irma Soldevilla-Gallardo, Anna Scavuzzo, Miguel Angel Jimenez-Ríos, Francisco Osvaldo García-Pérez
Diagnostic Performance of 99m Tc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18 F-PSMA-1007 PET/CT. Cancers 15 (24) (2023)